nach oben

International Journal of Clinical Oncology

Erschienen in:

13.09.2016 | Original Article

Comparison of plasma amino acid profile-based index and CA125 in the diagnosis of epithelial ovarian cancers and borderline malignant tumors

verfasst von: Etsuko Miyagi, Yasuyo Maruyama, Tae Mogami, Reiko Numazaki, Atsuko Ikeda, Hiroshi Yamamoto, Fumiki Hirahara

Erschienen in: International Journal of Clinical Oncology | Ausgabe 1/2017

Einloggen, um Zugang zu erhalten

Abstract

Background

We previously developed a new plasma amino acid profile-based index (API) to detect ovarian, cervical, and endometrial cancers. Here, we compared API to serum cancer antigen 125 (CA125) for distinguishing epithelial ovarian malignant tumors from benign growths.

Methods

API and CA125 were measured preoperatively in patients with ovarian tumors, which were later classified into 59 epithelial ovarian cancers, 21 epithelial borderline malignant tumors, and 97 benign tumors including 40 endometriotic cysts. The diagnostic accuracy and cutoff points of API were evaluated using receiver operating characteristic (ROC) curves.

Results

The area under the ROC curves showed the equivalent performance of API and CA125 to discriminate between malignant/borderline malignant and benign tumors (both 0.77), and API was superior to CA125 for discrimination between malignant/borderline malignant lesions and endometriotic cysts (API, 0.75 vs. CA125, 0.59; p < 0.05). At the API cutoff level of 6.0, API and CA125 had equal positive rates of detecting cancers and borderline malignancies (API, 0.71 vs. CA125, 0.74; p = 0.84) or cancers alone (API, 0.73 vs. CA125, 0.85; p = 0.12). However, API had a significantly lower detection rate of benign endometriotic cysts (0.35; 95 % CI, 0.21–0.52) compared with that of CA125 (0.65; 95 % CI, 0.48–0.79) (p < 0.05).

Conclusions

API is an effective new tumor marker to detect ovarian cancers and borderline malignancies with a low false-positive rate for endometriosis. A large-scale prospective clinical study using the cutoff value of API determined in this study is warranted to validate API for practical clinical use.

GLOBOCAN 2012: estimated cancer mortality, incidence and prevalence worldwide in 2012. http://globocan.iarc.fr/Pages/fact_sheets_population.aspx. Accessed March 2016

Cancer Registry and Statistics. Cancer Information Service, National Cancer Center, Japan. http://ganjoho.jp/professional/statistics/statistics.html. Accessed March 2016

Yamagami W, Aoki D (2015) Annual report of the Committee on Gynecologic Oncology, the Japan Society of Obstetrics and Gynecology. J Obstet Gynaecol Res 41:1861–1869CrossRefPubMed

Lu KH, Skates S, Hernandez MA et al (2013) A 2-stage ovarian cancer screening strategy using the risk of ovarian cancer algorithm (ROCA) identifies early-stage incident cancers and demonstrates high positive predictive value. Cancer (Phila) 119:3454–3461CrossRef

Siegel RL, Miller KD, Jemal A (2015) Cancer statistics 2015. CA Cancer J Clin 65:5–29CrossRefPubMed

Cohen JG, White M, Cruz A et al (2014) In 2014, can we do better than CA125 in the early detection of ovarian cancer? World J Biol Chem 5:286–300CrossRefPubMedPubMedCentral

Jacobs I, Stabile I, Bridges J et al (1988) Multimodal approach to screening for ovarian cancer. Lancet 8580:268–271CrossRef

Menon U, Talaat A, Rosenthal AN et al (2014) Performance of ultrasound as a second line test to serum CA125 in ovarian cancer screening. BJOG 121(suppl 7):35–39CrossRefPubMed

Rocconi RP, Matthews KS, Kemper MK et al (2009) The timing of normalization of CA-125 levels during primary chemotherapy is predictive of survival in patients with epithelial ovarian cancer. Gynecol Oncol 114:242–245CrossRefPubMed

10.

Cascino A, Muscaritoli M, Cangiano C et al (1995) Plasma amino acid imbalance in patients with lung and breast cancer. Anti-Cancer Res 15:507–510

11.

Kubota A, Meguid MM, Hitch DC (1992) Amino acid profiles correlate diagnostically with organ site in three kinds of malignant tumors. Cancer (Phila) 69:2343–2348CrossRef

12.

Miyagi Y, Higashiyama M, Gochi A et al (2011) Plasma free amino acid profiling of five types of cancer patients and its application for early detection. PLoS One 6:e24143CrossRefPubMedPubMedCentral

13.

Okamoto N (2012) Use of “AminoIndex technology” for cancer screening (in Japanese). Ningen Dock 26:911–922

14.

Ihata Y, Miyagi E, Numazaki R et al (2014) Amino acid profile index for early detection of endometrial cancer: verification as a novel diagnostic marker. Int J Clin Oncol 19:364–372CrossRefPubMed

15.

Fukutake N, Ueno M, Hiraoka N et al (2015) A novel multivariate index for pancreatic cancer detection based on the plasma free amino acid profile. PLoS One 10:e0132223CrossRefPubMedPubMedCentral

16.

Miyagi E, Numazaki R, Nakanishi T et al (2012) Diagnostic performance and clinical utility of novel gynecologic cancer screening method based on “Aminoindex Technology” (in Japanese). Ningen Dock 26:749–755

17.

Shimbo K, Oonuki T, Yahashi A et al (2009) Precolumn derivatization reagents for high-speed analysis of amines and amino acids in biological fluid using liquid chromatography/electrospray ionization tandem mass spectrometry. Rapid Commun Mass Spectrom 23:1483–1492CrossRefPubMed

18.

Shimbo K, Yahashi A, Hirayama K et al (2009) Multifunctional and highly sensitive precolumn reagents for amino acids in liquid chromatography/tandem mass spectrometry. Anal Chem 81:5172–5179CrossRefPubMed

19.

Shimbo K, Kubo S, Harada Y et al (2010) Automated precolumn derivatization system for analyzing physiological amino acids by liquid chromatography/mass spectrometry. Biomed Chromatogr 24:683–691CrossRefPubMed

20.

Proenza AM, Oliver J, Palou A et al (2003) Breast and lung cancer are associated with a decrease in blood cell amino acid content. J Nutr Biochem 14:133–138CrossRefPubMed

21.

Okamoto N, Miyagi Y, Chiba A et al (2009) Diagnostic modeling with differences in plasma amino acid profiles between non-cachectic colorectal/breast cancer patients and healthy individuals. Int J Med Med Sci 1:1–8

22.

Maeda J, Higashiyama M, Imaizumi A et al (2010) Possibility of multivariate function composed of plasma amino acid profiles as a novel screening index for non-small cell lung cancer: a case control study. BMC Cancer 10:690CrossRefPubMedPubMedCentral

23.

Munn DH, Mellor AL (2013) Indoleamine 2,3 dioxygenase and metabolic control of immune responses. Trends Immunol 34:137–143CrossRefPubMed

24.

Suzuki Y, Suda T, Furuhashi K et al (2010) Increased serum kynurenine/tryptophan ratio correlates with disease progression in lung cancer. Lung Cancer 67:361–365CrossRefPubMed

25.

Cho KR, IeM Shih (2009) Ovarian cancer. Annu Rev Pathol 4:287–313CrossRefPubMedPubMedCentral

26.

Kadan Y, Fiascone S, McCourt C et al (2015) Predictive factors for the presence of malignant transformation of pelvic endometriosis. Eur J Obstet Gynecol Reprod Biol 185:23–27CrossRefPubMed

27.

Jacobs IJ, Menon U, Ryan A et al (2015) Ovarian cancer screening and mortality in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomized controlled trial. Lancet 10022:945–956

28.

Haruta S, Furukawa N, Yoshizawa Y et al (2011) Molecular genetics and epidemiology of epithelial ovarian cancer. Oncol Rep 26:1347–1356PubMed

Titel: Comparison of plasma amino acid profile-based index and CA125 in the diagnosis of epithelial ovarian cancers and borderline malignant tumors
verfasst von: Etsuko Miyagi
Yasuyo Maruyama
Tae Mogami
Reiko Numazaki
Atsuko Ikeda
Hiroshi Yamamoto
Fumiki Hirahara
Publikationsdatum: 13.09.2016
Verlag: Springer Japan
Erschienen in: International Journal of Clinical Oncology / Ausgabe 1/2017
Print ISSN: 1341-9625
Elektronische ISSN: 1437-7772
DOI: https://doi.org/10.1007/s10147-016-1035-4

Neu im Fachgebiet Onkologie

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

So sicher sind Tattoos: Neue Daten zur Risikobewertung

22.05.2024 Melanom Nachrichten

Das größte medizinische Problem bei Tattoos bleiben allergische Reaktionen. Melanome werden dadurch offensichtlich nicht gefördert, die Farbpigmente könnten aber andere Tumoren begünstigen.

CAR-M-Zellen: Warten auf das große Fressen

22.05.2024 Onkologische Immuntherapie Nachrichten

Auch myeloide Immunzellen lassen sich mit chimären Antigenrezeptoren gegen Tumoren ausstatten. Solche CAR-Fresszell-Therapien werden jetzt für solide Tumoren entwickelt. Künftig soll dieser Prozess nicht mehr ex vivo, sondern per mRNA im Körper der Betroffenen erfolgen.

Blutdrucksenkung könnte Uterusmyome verhindern

21.05.2024 Krebsvorsorge in der Gynäkologie Nachrichten

Frauen mit unbehandelter oder neu auftretender Hypertonie haben ein deutlich erhöhtes Risiko für Uterusmyome. Eine Therapie mit Antihypertensiva geht hingegen mit einer verringerten Inzidenz der gutartigen Tumoren einher.

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Comparison of plasma amino acid profile-based index and CA125 in the diagnosis of epithelial ovarian cancers and borderline malignant tumors